Why the study?
Do angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients with congestive heart failure and after myocardial infarction?
Population
Patients with congestive heart failure (CHF) and after myocardial infarction (MI)
Design
Review
Authors
Loading...
Supports indefinite ACE inhibitor use in symptomatic CHF; confirms prior trial benefits but leaves optimal duration in asymptomatic post-MI open.
Do angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients with congestive heart failure and after myocardial infarction?
This review highlights that ACE inhibitors reduce morbidity and mortality in patients with symptomatic congestive heart failure and post-myocardial infarction, supporting their indefinite use in symptomatic patients.
Nelson et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: